%0 Journal Article %A Sarah AE Rupprechter %A Derek J Sloan %A Wilna Oosthuyzen %A Till T Bachmann %A Adam T Hill %A Kevin Dhaliwal %A Kate Templeton %A Joshua Matovu %A Christine Sekaggya-Wiltshire %A James W Dear %T Cytokeratin-18 has potential as a biomarker of drug-induced liver injury in European and African patients on treatment for tuberculosis %D 2020 %R 10.1101/2020.06.03.20121038 %J medRxiv %P 2020.06.03.20121038 %X Patients on anti-tuberculosis (anti-TB) therapy are at risk of developing drug-induced liver injury (DILI). Cytokeratin-18 (K18) is an exploratory DILI biomarker that has been developed predominately in Caucasian populations and not African populations in whom TB is common. Our aim was to determine the K18 concentration in different populations with mycobacterial infection and investigate whether K18 has potential as a biomarker of anti-TB DILI.European patients receiving anti-TB therapy were recruited at the Royal Infirmary of Edinburgh, UK (ALISTER - ClinicalTrials.gov Identifier: NCT03211208). African patients with HIV-TB coinfection, receiving anti-TB and anti-retroviral therapy (ART), were recruited at the Infectious Diseases Institute, Kampala, Uganda (SAEFRIF - NCT03982277). Serial blood samples, demographic and clinical data were collected. K18 was quantified using the M65 ELISA.The study had 235 participants (healthy volunteers (n=28); ALISTER: active TB (n=30), latent TB (n=88), non-tuberculous mycobacterial infection (n=25); SAEFRIF: HIV-TB coinfection (n=64)). There was no difference in K18 across the groups and treatment did not affect K18 in the absence of DILI. Alanine transaminase activity (ALT) and K18 were correlated (r=0.42, 95%CI=0.34-0.49, P<0.0001). Variability was higher for K18 than ALT. There were two DILI cases: baseline ALT was 18 and 28 IU/1, peak ALT 431 and 194 IU/L; baseline K18 58 and 219 U/L, peak K18 1247 and 3490 U/L, respectively.Circulating K18 was comparable in UK and Ugandan patients. K18 correlated with ALT and increased with DILI. Further work should determine the diagnostic and prognostic utility of K18 in this global context-of-use.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03211208Funding StatementSarah Rupprechter acknowledges the MRC and University of Edinburgh for PhD studentship funding. JWD was supported by an NHS Research Scotland (NRS) Career Research Fellowship through NHS Lothian and acknowledges the contribution of the British Heart Foundation Centre of Research Excellence Award.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Full written informed consent was obtained from every participant and the study was approved by the West of Scotland Research Ethics Committee. This trial was approved by a local research and ethics committee, the National Drug Authority and the Uganda National Council for Science and Technology. The study was performed in accordance with the general principles in the International Ethical Guidelines for Biomedical Research Involving Human Subjects and the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be available on request %U https://www.medrxiv.org/content/medrxiv/early/2020/06/04/2020.06.03.20121038.full.pdf